Farquhar John C.M., the Chief Executive Officer of Heartflow, Inc., recently sold 38,900 shares of the company's stock. This transaction occurred on October 12, 2026, and is part of a pre-arranged trading plan that was adopted on September 12, 2025. The sale is significant as it reflects the CEO's strategic financial decisions and may influence investor sentiment.
Heartflow, Inc. is a company focused on surgical and medical instruments and apparatus. It operates under the SIC code 3841. The firm is incorporated in Delaware and has its business address in San Francisco, California. The company trades under the ticker symbol HTFL.
According to the filing, the transaction was executed at a weighted average price of $49.568 per share, with prices ranging from $49.52 to $50.00. Following this sale, Farquhar retains ownership of 283,014 shares of Heartflow. The filing notes that the transaction was made in compliance with Rule 10b5-1, which allows executives to set up a predetermined plan for selling stock to avoid accusations of insider trading.
This sale may have implications for Heartflow's shareholders and the broader surgical and medical instruments industry. Investors often scrutinize executive transactions for indications of a company's future performance. Heartflow's competitors may also be monitoring the market's reaction to this sale as they strategize their own executive actions and investor communications.
The filing does not specify any immediate next steps following this transaction.